Tonix Pharmaceuticals is getting into the addiction business, licensing a phase 2 treatment for cocaine intoxication from Columbia University. The company is planning to start a pivotal trial for the enzyme, which breaks down cocaine, in 2020.

We issued an updated report on Catalyst Pharmaceuticals Inc. CPRX on May 21. In November 2018, the company’s Firdapse (amifampridine) tablets obtained FDA approval for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. The drug became the first FDA-approved treatment for LEMS and also the first approved product in Catalyst’s portfolio.

Clinical stage regenerative medicine company, SpinalCyte, now features research studies on its website outlining the potential benefits of fibroblast technology.